Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

<i>MGMT</i> promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas

7 Jan 2022

Abstract excerpt

O 6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is an important predictor of response to alkylating chemotherapy in glioblastomas.1 A common method to determine MGMT promoter status is with the MGMT-STP27 algorithm which is calculated from the methylation levels of two specific CpGs (cg12434587 and cg12981137) on Illumina DNA methylation arrays.2 This algorithm was constructed with data from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Metastases and Treatment
Share to Glioma Diagnosis and Treatment
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35099533
DOI: 10.1093/neuonc/noac014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

<i>MGMT</i> promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomasPMID 35099533Read ↗

Clinical value of the MGMT promoter methylation score in IDHmt low-grade glioma for predicting benefit from temozolomide treatmentSemantic proximity Read ↗

MGMT promoter methylation and survival following chemotherapy for WHO grade 4 IDH-mutant astrocytomaSemantic proximity Read ↗

MGMT promoter methylation is associated with patient age and 1p/19q status in IDH-mutant gliomasSemantic proximity Read ↗

Prognostic value of O6-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomasSemantic proximity Read ↗

Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating ChemotherapySemantic proximity Read ↗

MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.Semantic proximity Read ↗

Prognostic significance of O6-methylguanine-DNA methyltransferase promoter methylation status in isocitrate dehydrogenase-mutant glioma.Semantic proximity Read ↗

The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients' survival.Semantic proximity Read ↗

DNA Methylation Profiling in IDH-Mutant Gliomas: Biological Evolution, Molecular Grading and Clinical Implementation.Semantic proximity Read ↗

<i>MGMT-</i>Methylated Alleles Are Distributed Heterogeneously Within Glioma Samples Irrespective of<i>IDH</i>Status and Chromosome 10q DeletionSemantic proximity Read ↗

Combined <i>MGMT</i> Expression and MMR Deficiency Underlie Poor Outcomes of Temozolomide in <i>IDH</i> -Wildtype Grade 2 GliomasSemantic proximity Read ↗

MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.